Relationship Between Fasting C-Peptide to Diabetes Duration Ratio (FCP/DD) and Diabetic Peripheral Neuropathy
Yueyue Fu,Yuling Xing,Linlin Yang,Jing Liu,Huijuan Ma
DOI: https://doi.org/10.2147/dmso.s491560
2024-11-28
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Yueyue Fu, 1 Yuling Xing, 2 Linlin Yang, 3 Jing Liu, 2 Huijuan Ma 3 1 Graduate School of North China University of Science and Technology, Tangshan, People's Republic of China; 2 Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's Republic of China; 3 Department of Endocrinology, the First Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China Correspondence: Jing Liu, Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's Republic of China, Tel +86 13673186039, Email Huijuan Ma, Department of Endocrinology, the First Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China, Tel +86 18032838686, Email Purpose: To explore the correlation between fasting C-peptide to diabetes duration ratio (FCP/DD) and diabetic peripheral neuropathy (DPN). Methods: The study was conducted on 816 patients with type 2 diabetes (T2DM). Subjects were classified into a diabetic peripheral neuropathy group (DPN, n=408) and a non-diabetic peripheral neuropathy group (NDPN, n=408) depending on the presence of DPN. Collected patients' baseline data, calculated the FCP/DD ratio, and analyzed the correlation between FCP/DD and DPN. Results: A comparative analysis of general characteristics revealed that the DPN group exhibited higher values for age, DD, proportion of hypertension, proportion of DN, and proportion of DR compared to the NDPN group, Conversely, the DPN group demonstrated lower proportions of eGFR, FCP/DD, FCP, and fatty liver relative to the NDPN group, with all differences achieving statistical significance (P < 0.05). Compared to the high FCP/DD group, the low FCP/DD group exhibited higher values in age, DD, the proportion of DPN, DN, DR, and hypertension, as well as elevated levels of HDL-C and NEUT (P< 0.05). Conversely, the low FCP/DD group demonstrated a lower proportion of patients who smoked and those with fatty liver, along with reduced BMI, ALB, FBG, UA, eGFR, TC, TG, and LDL-C levels (P < 0.05). In patients with T2DM, after adjusting for confounding factors, high levels of FCP/DD were found to be a protective factor for DPN (P < 0.05). The area under the curve of the FCP/DD Model predicting DPN (AUC=0.737) was higher than that of single FCP (AUC=0.587), DD (AUC=0.665). Conclusion: The high FCP/DD ratio was a protective factor for T2DM with DPN. Additionally, the FCP/DD ratio was found to be a better predictor for the occurrence of DPN in T2DM compared to FCP and DD alone. Keywords: Diabetic peripheral neuropathy, type 2 diabetes, FCP/DD Diabetes is still one of the most significant public health concerns today, with 451 million people globally living with diabetes in 2017. This number is expected to increase to as many as 693 million by 2045. 1 The high prevalence of chronic complications of diabetes significantly impacts the quality of life and longevity of patients. 2 Diabetic peripheral neuropathy (DPN) is one of the common complications affecting approximately 50% of patients with diabetes (type 1 diabetes and type 2 diabetes). 3 Diabetic Peripheral Neuropathy (DPN) can result in numbness and pain in the lower extremities, foot ulcers, and potentially necessitate amputation, thereby markedly diminishing patients' quality of life. The onset of DPN is often insidious, with up to 50% of affected individuals remaining asymptomatic during the initial stages, which frequently leads to neglect and delayed diagnosis. Therefore, early prevention and detection of diabetic peripheral neuropathy are of paramount importance. 4 The pathogenesis of Diabetic Peripheral Neuropathy (DPN) is multifaceted, encompassing oxidative stress, inflammatory responses, neurotrophic dysregulation and various other contributing factors. 5–7 Wahren et al 8 showed that compared with the placebo group, injected C-peptide analogues can increase the vibration perception thresholds; This indicates that C-peptide replacement therapy may enhance neurological function in patients with diabetic peripheral neuropathy (DPN). C-peptide, a byproduct of glucagon, is more stable than insulin. C-peptide levels and release profiles are commonly used to assess islet function. 9 Umaid Potaliya et al 10 demonstrated that lower serum C-peptide levels are linked to diabetic peripheral neuropathy (DPN) in people with type 2 diabetes, they also found that the risk of DPN increases with longer duration of diabetes. 11 Some studies have shown that C-peptide at physiological concentrations has anti-inflammatory, immunomodulatory, and neurotrophic effects, C-peptide and its analogs have been found to lower bloo -Abstract Truncated-
endocrinology & metabolism